Evidence map›Paper›PMID 41140811›Full record

ArticleBrain communications2025

Plasma phosphorylated tau-217 correlates with brain atrophy, cognition, and cerebrospinal fluid biomarkers in a cognitively healthy community cohort.

Ming Ann Sim, Ella Rowsthorn, William T O'Brien, Mujun Sun, Lachlan Cribb, Katherine Franks, Stuart J McDonald, Stephanie Yiallourou, Marina Cavuoto, Ian H Harding and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ming Ann SimSchool of Psychological Science and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Clayton 3800, Australia.
Ella RowsthornSchool of Psychological Science and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Clayton 3800, Australia.ORCID https://orcid.org/0000-0003-4882-4183
William T O'BrienDepartment of Neurology, Alfred Health, Melbourne 3004, Australia.
Mujun SunSchool of Psychological Science and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Clayton 3800, Australia.
Lachlan CribbSchool of Psychological Science and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Clayton 3800, Australia.
Katherine FranksSchool of Psychological Science and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Clayton 3800, Australia.
Stuart J McDonaldDepartment of Neuroscience, The School of Translational Medicine, Monash University, Melbourne 3004, Australia.
Stephanie YiallourouSchool of Psychological Science and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Clayton 3800, Australia.
Marina CavuotoSchool of Psychological Science and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Clayton 3800, Australia.
Ian H HardingDepartment of Neurology, Alfred Health, Melbourne 3004, Australia.
Trevor T J ChongSchool of Psychological Science and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Clayton 3800, Australia.ORCID https://orcid.org/0000-0001-7764-3811
Meng LawSchool of Psychological Science and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Clayton 3800, Australia.
Terence J O'BrienSchool of Psychological Science and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Clayton 3800, Australia.
Lucy VivashSchool of Psychological Science and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Clayton 3800, Australia.ORCID https://orcid.org/0000-0002-1182-0907
Matthew P PaseSchool of Psychological Science and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Clayton 3800, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasma biomarkers are promising for detecting Alzheimer's disease (AD) pathology, but their role in cognitively healthy individuals remains unclear. Plasma pTau-217 has high diagnostic accuracy for clinical and prodromal AD, yet its relevance in preclinical stages is underexplored. We examined if plasma biomarkers of AD, neurodegeneration, and neuroinflammation were associated with cognition, brain structure, and their cerebrospinal fluid (CSF) counterparts in dementia-free older adults. We studied community-based, dementia-free older adults from the Brain and Cognitive Health (BACH) cohort. Neuropsychological testing assessed global cognition (MMSE), memory (Logical Memory II), visual processing (Hooper Visual Organization Test), processing speed (Trail Making Test-A), and reasoning (Similarities). Paired plasma and CSF biomarkers [phosphorylated Tau-217 (pTau-217), phosphorylated Tau-181 (pTau-181), Glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), amyloid-beta 42/40 (Aβ42/40)] were measured using Single molecule arrays (SIMOA). Brain magnetic resonance imaging (MRI)-derived cortical thickness was used as a neurodegeneration marker. Multivariable linear regression assessed associations between log

Indexed as

biomarkercerebrospinal fluidcognitionplasma

Identifiers

PMID41140811
PMCPMC12550561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.